Please assess the completion status of the following clinical trial:

Trial Title: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 18 years of age upon entry into screening.~* Documented history of migraine with or without aura according to the IHS ICHD-III for greater than or equal to 12 months~* Has EM defined as history of greater than or equal to 4 and less than 15 migraine days and less than 15 headache days per month on average during the 3 months prior to initial screening~* Employed greater than or equal to 20 hours/week upon entry into initial screening, stable for at least 3 months in the same job and has not specified willful termination of employment throughout the duration of the study. Employment is defined by work outside the home, self-employed, or works from home~* Has greater than or equal to 4 hours of lost productive time due to headache/migraine and/or related symptoms in the past month prior to initial screening as determined by subject~* Has total disability score of greater than 10 as assessed by MIDAS (3-month recall) at initial screening~* History of treatment failure with at least 1 preventive treatment category for migraine~Exclusion Criteria:~* Older than 50 years of age at migraine onset~* History of cluster headache, hemiplegic migraine, or other trigeminal autonomic cephalalgia.~* Taken an opioid and/or opioid-containing analgesic greater than or equal to 4 days during the 1 month prior to screening for any indication~* Taken a butalbital and/or butalbital-containing analgesic greater than or equal to 4 days during the 1 month prior to screening for any indication~* Change in the regimen of current migraine preventive treatment or a concomitant medication that may have migraine prevention effects during baseline~* Taken an opioid and/or opioid-containing analgesic ≥ 4 days during baseline for any indication.~* Taken a butalbital and/or butalbital-containing analgesic ≥ 4 days during baseline for any indication.~* Previously treated with any agent (monoclonal antibody or small molecule) targeting the CGRP pathway (ligand or receptor) in preventive settings~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.
- Erenumab (Type: EXPERIMENTAL): After subjects complete baseline and are found eligible, they will be enrolled and randomized in a 1:1 ratio to either erenumab or placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).